AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11336160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose malabsorption (breath deltaH2 production >20 ppm)
Number of subjects: 50
Study 11336160 — intervention group
Group type: COMPARATOR
Intervention: Normal fructose absorption
Number of subjects: 50
Study 9399445 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (<72 hours after spinal cord injury)
Number of subjects: 0
Study 9399445 — intervention group
Group type: COMPARATOR
Intervention: Late surgery (>5 days after spinal cord injury)
Number of subjects: 0
Study 8199601 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 30
Study 8199601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3297176 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 42
Study 3297176 — intervention group
Group type: EXPERIMENTAL
Intervention: phenelzine
Number of subjects: 42
Study 3297176 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 31077858 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterials in outpatient prescriptions at township health centers
Number of subjects: 17
Study 31077858 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterials in outpatient prescriptions at community health service centers
Number of subjects: 17
Study 31077858 — intervention group
Group type: COMPARATOR
Intervention: Comparison between hospital A and hospital N in township health centers
Number of subjects: 17
Study 31077858 — intervention group
Group type: COMPARATOR
Intervention: Comparison between P center and T center
Number of subjects: 17
Study 28374183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (group R)
Number of subjects: 0
Study 28374183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and dexmedetomidine (group RD)
Number of subjects: 0
Study 28374183 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 0
Study 25940520 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption at any time
Number of subjects: 11219
Study 25940520 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent DAPT discontinuation before 30 days
Number of subjects: 11219
Study 25940520 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent DAPT discontinuation between 30 and 90 days
Number of subjects: 11219
Study 25940520 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT discontinuation beyond 90 days
Number of subjects: 11219
Study 23609776 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble wheat bran fibre-containing breakfast cereal (5.4 g fibre, 3.5 g from wheat bran)
Number of subjects: 153
Study 21606430 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus DTIC (10 mg/m2/min at 1800 mg/m2 followed by DTIC at 500 mg/m2 every 2 weeks)
Number of subjects: 113
Study 21606430 — intervention group
Group type: COMPARATOR
Intervention: DTIC alone (1200 mg/m2 every 3 weeks)
Number of subjects: 113
Study 19194189 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation to lactating nonanemic mothers
Number of subjects: 47
Study 19194189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19194189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maternal iron reserves
Number of subjects: 47
Study 19194189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Hb level (<12 g/dL)
Number of subjects: 47
Study 16126256 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with rtPA
Number of subjects: 108
Study 16126256 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic treatment (Control)
Number of subjects: 108
Study 15330958 — intervention group
Group type: EXPERIMENTAL
Intervention: 22‐G hollow needle (group I)
Number of subjects: 70
Study 15330958 — intervention group
Group type: COMPARATOR
Intervention: 22‐G caudal block needle (group II)
Number of subjects: 70
Study 11233236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (40 Gy radiation, low-dose fraction cisplatin 7 mg/body/day for 5 days a week for 4 weeks, and 5-fluorouracil 350 mg/body/day for 28 days)
Number of subjects: 40
Study 11233236 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (high-dose fraction cisplatin 70 mg/m2/day on day 1 and 5-fluorouracil 700 mg/m2/day on days 1-5)
Number of subjects: 40
Study 9253574 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution alone (Group C)
Number of subjects: 40
Study 9253574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PGE1-induced hypotension and haemodilution (Group D)
Number of subjects: 40
Study 9253574 — intervention group
Group type: COMPARATOR
Intervention: PGE1-induced hypotension alone (Group B)
Number of subjects: 40
Study 9253574 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 40
Study 9253574 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups post-surgery
Number of subjects: 40
Study 8494421 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (UWS)
Number of subjects: 39
Study 8494421 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas' Hospital solution (STS)
Number of subjects: 39
Study 31296654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization events (recurrent stroke, myocardial infarction, major bleeding, serious adverse events) in stroke cohort
Number of subjects: 6047
Study 31296654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization events (recurrent stroke, myocardial infarction, major bleeding, serious adverse events) in TIA cohort
Number of subjects: 6047
Study 31296654 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS score
Number of subjects: 6047
Study 31296654 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb weakness
Number of subjects: 6047
Study 31296654 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability at 90 days in stroke patients
Number of subjects: 6047
Study 31296654 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability at 90 days in TIA patients
Number of subjects: 6047
Study 29522355 — intervention group
Group type: EXPERIMENTAL
Intervention: NaNO3 supplementation (1 g/day, n = 13)
Number of subjects: 21
Study 29522355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose, n = 8)
Number of subjects: 21
Study 27980499 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg∙kg‐1 body mass anhydrous caffeine)
Number of subjects: 10
Study 27980499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial sweetener)
Number of subjects: 10
Study 27980499 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 10
Study 25319951 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg 12 h before PCI, and a further 20 mg 2 h preprocedure)
Number of subjects: 159
Study 25319951 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 159
Study 25319951 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 159
Study 22678167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 212
Study 22678167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (DS twice daily)
Number of subjects: 212
Study 22678167 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 212
Study 19669674 — intervention group
Group type: EXPERIMENTAL
Intervention: Keshet program (experimental group)
Number of subjects: 49
Study 19669674 — intervention group
Group type: COMPARATOR
Intervention: No structural intervention (control group)
Number of subjects: 49
Study 18432390 — intervention group
Group type: COMPARATOR
Intervention: Advertising prewarning (before the episode)
Number of subjects: 250
Study 18432390 — intervention group
Group type: COMPARATOR
Intervention: Health warning (after the episode)
Number of subjects: 250
Study 18432390 — intervention group
Group type: COMPARATOR
Intervention: No warning (control condition)
Number of subjects: 250
Study 15732545 — intervention group
Group type: EXPERIMENTAL
Intervention: Material A (Affinis, Coltène/Whaledent)
Number of subjects: 130
Study 15732545 — intervention group
Group type: COMPARATOR
Intervention: Material B (control)
Number of subjects: 130
Study 15732545 — intervention group
Group type: EXPERIMENTAL
Intervention: Material A
Number of subjects: 130
Study 12602406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and glucose-lowering sulphonylurea
Number of subjects: 0
Study 12602406 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea alone
Number of subjects: 0
Study 10561675 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg levonorgestrel with 20 microg ethinyl estradiol
Number of subjects: 155
Study 10561675 — intervention group
Group type: COMPARATOR
Intervention: Triphasic norethindrone with ethinyl estradiol
Number of subjects: 155
Study 8763311 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 115
Study 8763311 — intervention group
Group type: COMPARATOR
Intervention: 2.5% phenylephrine
Number of subjects: 115
Study 1832101 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (aided by parent or staff)
Number of subjects: 23
Study 1832101 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (unaided)
Number of subjects: 23
Study 1832101 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (aided by parent or staff)
Number of subjects: 23
Study 1832101 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (unaided)
Number of subjects: 23
Study 6871054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 17
Study 6871054 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 17
Study 30052328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicapistat 400- or 800-mg twice-daily doses
Number of subjects: 0
Study 30052328 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg twice daily (active control)
Number of subjects: 0
Study 30052328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicapistat (various doses)
Number of subjects: 0
Study 29521283 — intervention group
Group type: EXPERIMENTAL
Intervention: FDAE group (Group E)
Number of subjects: 302
Study 29521283 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 302
Study 26712571 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 95
Study 26712571 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 95
Study 25082956 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-ankle-foot orthosis equipped with an Ultraflex ankle power unit, used for at least 6 hours every other night for one year.
Number of subjects: 28
Study 25082956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no knee-ankle-foot orthosis).
Number of subjects: 28
Study 25082956 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-ankle-foot orthosis wearing time.
Number of subjects: 28
Study 25082956 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome measures (ankle-foot and knee angle in gait, gross motor function).
Number of subjects: 28
Study 22246217 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing physical activity (2 sessions of 90 minutes per week for 9 months)
Number of subjects: 59
Study 19460767 — intervention group
Group type: EXPERIMENTAL
Intervention: ADX10059 250 mg tds
Number of subjects: 24
Study 19460767 — intervention group
Group type: EXPERIMENTAL
Intervention: ADX10059 50 mg tds
Number of subjects: 24
Study 19460767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17172351 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 60 mg/m2 and cisplatin 50 mg/m2
Number of subjects: 101
Study 17172351 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel 175 mg/m2 and cisplatin 50 mg/m2
Number of subjects: 101
Study 15367301 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial analgesia (intrathecal and epidural)
Number of subjects: 87
Study 11592667 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial menu map with visual momentum design
Number of subjects: 0
Study 11592667 — intervention group
Group type: COMPARATOR
Intervention: Partial menu map without visual momentum
Number of subjects: 0
Study 11592667 — intervention group
Group type: COMPARATOR
Intervention: Command-only representation
Number of subjects: 0
Study 9480998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 52
Study 9480998 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 52
Study 7672876 — intervention group
Group type: EXPERIMENTAL
Intervention: Contractubex gel (10% onion extract, 50/U of sodium heparin per 1g of gel, 1% allantoin), applied topically for one year starting 26 days post-operation.
Number of subjects: 45
Study 7672876 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 45
Study 2919059 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.1% mouthrinses (rinsed four times daily)
Number of subjects: 30
Study 2919059 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinses
Number of subjects: 30
Study 31978826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high intensity progressive resistance and computerised cognitive training (PRT+CCT)
Number of subjects: 100
Study 31978826 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical resistance training (PRT)
Number of subjects: 100
Study 31978826 — intervention group
Group type: COMPARATOR
Intervention: Sham physical+sham cognitive training (SHAM+SHAM)
Number of subjects: 100
Study 30579584 — intervention group
Group type: EXPERIMENTAL
Intervention: Care within a medical home
Number of subjects: 202
Study 30579584 — intervention group
Group type: COMPARATOR
Intervention: Low socioeconomic status (young caregiver)
Number of subjects: 202
Study 30579584 — intervention group
Group type: COMPARATOR
Intervention: Low socioeconomic status (low education)
Number of subjects: 202
Study 30579584 — intervention group
Group type: COMPARATOR
Intervention: Delayed language
Number of subjects: 202
Study 30579584 — intervention group
Group type: COMPARATOR
Intervention: Degree of prematurity and neonatal clinic follow‐up participation
Number of subjects: 202
Study 24989482 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational strategies intervention (IG)
Number of subjects: 61
Study 24989482 — intervention group
Group type: COMPARATOR
Intervention: Standardized information (CG1)
Number of subjects: 61
Study 24989482 — intervention group
Group type: COMPARATOR
Intervention: Routine procedures (CG2)
Number of subjects: 61
Study 22849770 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐178882 (single dose 30 mg in fed state)
Number of subjects: 0
Study 22849770 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐178882 (multiple doses 30‐600 mg once daily for 14 days)
Number of subjects: 0
Study 22849770 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 0
Study 22849770 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐178882 (single doses 10‐1000 mg)
Number of subjects: 0
Study 22849770 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐178882 (multiple doses)
Number of subjects: 0
Study 22849770 — intervention group
Group type: COMPARATOR
Intervention: ACT‐178882 and Enalapril
Number of subjects: 0
Study 22849770 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐178882
Number of subjects: 0
Study 21742303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence photodynamic therapy (PDT)
Number of subjects: 16
Study 21742303 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injections of ranibizumab
Number of subjects: 16
Study 21742303 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 16
Study 19926780 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training mode
Number of subjects: 0
Study 19926780 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational training mode
Number of subjects: 0
Study 16826467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) - invitation, counselling, application support; 69% participated in a 3 week in-patient multidisciplinary rehabilitation program
Number of subjects: 230
Study 16826467 — intervention group
Group type: COMPARATOR
Intervention: Control group (KG) - usual care; 20% participated in a 3 week in-patient multidisciplinary rehabilitation program
Number of subjects: 230
Study 16826467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 230
Study 16826467 — intervention group
Group type: COMPARATOR
Intervention: Control group (KG)
Number of subjects: 230
Study 14695940 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term administration of a nutraceutical formulation based on coenzyme Q10, vitamin E, selenium, methionine, and phospholipids
Number of subjects: 0
Study 14695940 — intervention group
Group type: COMPARATOR
Intervention: Control group of city clerks
Number of subjects: 0
Study 10649623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc conjugate vaccine (1, 3, or 10 micrograms of PSs conjugated to diphtheria or tetanus toxoid)
Number of subjects: 0
Study 10649623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10649623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc conjugate vaccine
Number of subjects: 0
Study 8783392 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nicotine cigarette (0.7 mg)
Number of subjects: 0
Study 8783392 — intervention group
Group type: COMPARATOR
Intervention: Denicotinised cigarette (0.1 mg)
Number of subjects: 0
Study 1534287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (t-PA)
Number of subjects: 26
Study 1534287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2937411 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol hydrochloride (300 mg once daily for 4 weeks)
Number of subjects: 21
Study 2937411 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 2937411 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 21
Study 29453170 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping with the paretic leg
Number of subjects: 0
Study 29453170 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping with the non-paretic leg
Number of subjects: 0
Study 29453170 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping speed
Number of subjects: 0
Study 27636593 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) on the perilimbal sclera
Number of subjects: 30
Study 27636593 — intervention group
Group type: COMPARATOR
Intervention: Conventional SLT with gonioscopy lens
Number of subjects: 30
Study 26232049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IgG administered at replacement dosages
Number of subjects: 0
Study 23997136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hohmann procedure (50 feet)
Number of subjects: 101
Study 23997136 — intervention group
Group type: COMPARATOR
Intervention: Lapidus procedure (51 feet)
Number of subjects: 101
Study 23997136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hohmann procedure (subgroup with hypermobility)
Number of subjects: 101
Study 23997136 — intervention group
Group type: COMPARATOR
Intervention: Lapidus procedure (subgroup with hypermobility)
Number of subjects: 101
Study 20556613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (docetaxel with 150 mg single-dose oral casopitant)
Number of subjects: 14
Study 20556613 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (docetaxel without casopitant)
Number of subjects: 14
Study 20556613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Regimen A and Regimen B
Number of subjects: 14
Study 18940393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/d) with pioglitazone (30 mg/d)
Number of subjects: 0
Study 18940393 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (30 mg/d) + Placebo
Number of subjects: 0
Study 16801406 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 200 mg/day
Number of subjects: 0
Study 16801406 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day
Number of subjects: 0
Study 16801406 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine with lamivudine (100 mg/day)
Number of subjects: 0
Study 16801406 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine with adefovir dipivoxil (10 mg/day)
Number of subjects: 0
Study 16801406 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine with telbivudine
Number of subjects: 0
Study 16801406 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil with telbivudine
Number of subjects: 0
Study 12974995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 468
Study 12974995 — intervention group
Group type: COMPARATOR
Intervention: Placebo monotherapy
Number of subjects: 468
Study 12974995 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine augmentation
Number of subjects: 468
Study 12974995 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (in patients with lithium levels <=0.8 mequiv./l)
Number of subjects: 468
Study 12974995 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide monotherapy
Number of subjects: 468
Study 12974995 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 468
Study 10831173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusion of 3.3 mmol/kg lysine hydrochloride over 90 minutes
Number of subjects: 10
Study 9217380 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPCON HMS system
Number of subjects: 34
Study 9217380 — intervention group
Group type: COMPARATOR
Intervention: Classical ACT management
Number of subjects: 34
Study 7679615 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg b.i.d.)
Number of subjects: 11
Study 7679615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2425159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 32
Study 2425159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32